As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) remains a limiting factor, slowed by scalability challenges, bacterial contamination risks, and regulatory constraints.

Discover how Touchlight’s dbDNA™, a cell-free alternative to pDNA, is breaking through these bottlenecks.

In this whitepaper, you’ll learn:

• How dbDNA™ eliminates bacterial sequences and antibiotic resistance genes to streamline regulatory compliance
• Why dbDNA™ enhances production efficiency for rAAV and rLV vectors
• Real-world data comparing yields, reagent usage, and vector quality against pDNA workflows
• How dbDNA™ supports large-scale, safe, and scalable vector manufacturing for evolving clinical needs

Whether you’re troubleshooting upstream challenges or planning for commercial-scale production, this whitepaper offers the insights you need to move faster and go further.

Download the whitepaper to explore the data.